Arix leads USD152m Series B financing for Pyxis Oncology
Arix Bioscience (Arix), a global venture capital company focused on investing in and building breakthrough biotech companies, has invested in Pyxis Oncology (Pyxis). As part of the deal, Arix Managing Director Christian Schetter will join Pyxis’ Board of Directors. Pyxis is building a differentiated portfolio of biologics, including antibody-drug conjugates